ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Prospective Evaluation of Donor-Derived Cell-Free DNA (dd-cfDNA) in Monitoring Response to Anti-Rejection Treatment in Kidney Transplant Recipients with Indication Biopsy

L. Benning1, A. Fink2, F. Kälble1, C. Speer1, C. Nusshag1, M. Zeier1, C. Süsal3, C. Morath1, T. Tran2

1Department of Nephrology, University Hospital Heidelberg, Heidelberg, Germany, 2Transplantation Immunology, Institute of Immunology, University Hospital Heidelberg, Heidelberg, Germany, 3Transplant Immunology Research Center of Excellence, Koç University Hospital, Istanbul, Turkey

Meeting: 2022 American Transplant Congress

Abstract number: 1539

Keywords: Biopsy, Kidney transplantation, Outcome, Rejection

Topic: Basic Science » Basic Clinical Science » 17 - Biomarkers: Clinical Outcomes

Session Information

Session Name: Biomarkers: Clinical Outcomes

Session Type: Poster Abstract

Date: Tuesday, June 7, 2022

Session Time: 7:00pm-8:00pm

 Presentation Time: 7:00pm-8:00pm

Location: Hynes Halls C & D

*Purpose: Donor-derived cell-free DNA (dd-cfDNA) is a marker of allograft injury in kidney transplant recipients (KTR). Little is known about the possible use of dd-cfDNA in evaluating response to anti-rejection treatment in KTR showing histopathological signs of rejection.

*Methods: We are currently prospectively evaluating the diagnostic benefit of dd-cfDNA in 100 KTR undergoing indication biopsy. dd-cfDNA is quantified in the AlloSeq cfDNA assay (CareDx) at time of biopsy to estimate the association of dd-cfDNA levels with histopathological reporting. To assess the utility of dd-cfDNA in monitoring response to therapy, dd-cfDNA levels are quantified after initiation of treatment on days 7, 30, and 90 following biopsy.

*Results: Since December 2020, 56 KTR have been enrolled and 21/56 (38%) biopsies were graded as different types of rejection. Patients showing signs of active rejection had significantly higher levels of dd-cfDNA at time of biopsy than patients without any signs for rejection, whereas estimated glomerular filtration rate (eGFR) did not differ significantly between the two groups (P<0.01 and P=0.55, respectively, Figure 1A). In patients with antibody-mediated rejection (ABMR) or T-cell mediated rejection (TCMR), median (IQR) dd-cfDNA levels were highest with 3.4% (1.6-11.3) compared to the 0.4% (0.2-1.2) measured in patients with borderline changes and 0.2% (0.1-0.5) in patients with no signs of rejection. When considering only patients with ABMR or TCMR, we observe decreasing levels of dd-cfDNA following initiation of therapy (pooled slope -0.02; Figure 1B). In patients with borderline changes and low levels of dd-cfDNA (<1%) at time of biopsy we see an increase in eGFR after initiation of corticosteroid pulse therapy, whereas patients with high levels of dd-cfDNA (≥1%) show subsequent eGFR decline (Figure 1C).

*Conclusions: dd-cfDNA significantly discriminates active rejection at time of biopsy in KTR. Decreasing levels of dd-cfDNA may indicate treatment response in patients with ABMR and TCMR. dd-cfDNA may further help to identify borderline changes with favorable outcome from changes where additional therapy and closer monitoring is needed.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Benning L, Fink A, Kälble F, Speer C, Nusshag C, Zeier M, Süsal C, Morath C, Tran T. Prospective Evaluation of Donor-Derived Cell-Free DNA (dd-cfDNA) in Monitoring Response to Anti-Rejection Treatment in Kidney Transplant Recipients with Indication Biopsy [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/prospective-evaluation-of-donor-derived-cell-free-dna-dd-cfdna-in-monitoring-response-to-anti-rejection-treatment-in-kidney-transplant-recipients-with-indication-biopsy/. Accessed May 30, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences